StockNews.AI
EPIX
StockNews.AI
12 days

EPIX Deadline: EPIX Investors Have Opportunity to Lead ESSA Pharma Inc. Securities Fraud Lawsuit

1. Rosen Law Firm reminds EPIX investors of a class action lawsuit. 2. Class Period for securities purchases is December 12, 2023, to October 31, 2024. 3. Investors may be eligible for compensation without fees through contingency arrangements. 4. Lawsuit alleges misstatements about masofaniten's efficacy for prostate cancer treatment. 5. Potential damages incurred by investors following misleading public statements.

6 mins saved
Full Article

FAQ

Why Very Bearish?

The class action lawsuit indicates potential large financial liabilities for EPIX, reminiscent of previous biotech firms facing lawsuits due to misleading efficacy claims.

How important is it?

The article highlights serious allegations against EPIX that could greatly affect investor sentiment and stock value.

Why Short Term?

Immediate effects as the class action progresses and could influence stock performance in the near term.

Related Companies

ESSAAVEOPTN
NEW YORK, March 13, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ESSA Pharma Inc. (NASDAQ: EPIX) between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period"), of the important March 25, 2025 lead plaintiff deadline. So what: If you purchased ESSA Pharma securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the ESSA Pharma class action, go to https://rosenlegal.com/submit-form/?case_id=34133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 25, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, defendants, throughout the Class Period, failed to disclose to investors that: (1) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (2) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than defendants had led investors to believe; (3) the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint; (4) accordingly, defendants had overstated masofaniten's clinical, regulatory, and commercial prospects; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the ESSA Pharma class action, go to https://rosenlegal.com/submit-form/?case_id=34133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq.Phillip Kim, Esq.The Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827[email protected]www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A.

Related News